Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 2/20 | 0.50 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.47 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.47 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.46 |
| ▸ | FGF1 | P05230 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.43 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.43 |
| ▸ | FGF2 | P09038 | 1/20 | 0.42 |
| ▸ | VEGFA | P15692 | 1/20 | 0.42 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | STAT3 | P40763 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13560166 | 0.92 | LGALS3 (0.47) | IGF2RLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL14255515 | 0.92 | LGALS3 (0.47) | IGF2RLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL13867741 | 0.92 | LGALS3 (0.47) | IGF2RLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL13559835 | 0.92 | LGALS3 (0.47) | IGF2RLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL13288201 | 0.92 | LGALS3 (0.47) | IGF2RLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL13560177 | 0.92 | LGALS3 (0.47) | IGF2RLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL13559836 | 0.92 | LGALS3 (0.47) | IGF2RLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL10014356 | 0.90 | LGALS8 (0.52) | IGF2RLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL17087678 | 0.90 | LGALS8 (0.55) | IGF2RLGALS3LGALS9LGALS1LGALS7; LGALS7B | |
| SCHEMBL25142348 | 0.87 | MEN1 (0.54) | IGF2RLGALS3LGALS9LGALS1LGALS7; LGALS7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9289443-B2 | Pharmaceutical composition and method for preventing or treating hepatitis C | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2016-03-22 | — | — | US | disclosed |
| US-9289443-B2 | Pharmaceutical composition and method for preventing or treating hepatitis C | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2016-03-22 | — | — | US | disclosed |
| US-20120165279-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING OR TREATING HEPATITIS C | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-06-28 | — | — | US | disclosed |
| US-20120165279-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING OR TREATING HEPATITIS C | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165279-A1 | PHARMACEUTICAL COMPOSITION AND METHOD FOR PREVENTING OR TREATING HEPATITIS C | LIPC, HAVCR2, LIPA | IGF2R 4481/4885LGALS3 1079/4885LGALS9 1611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.